role of elispot assays in risk assessment pre- and post-kidney transplantation有关酶联免疫斑点试验的作用在风险评估和post-kidney移植.pdfVIP

Cells 2012, 1, 100-110; doi:10.3390/cells1020100 OPEN ACCESS cells ISSN 2073-4409 /journal/cells Review Role of ELISPOT Assays in Risk Assessment Pre- and Post-Kidney Transplantation Jennifer R. Zitzner * and Anat R. Tambur Comprehensive Transplant Center Feinberg School of Medicine, Northwestern University, 303 E Chicago Ave., Tarry Building Suite 11-703, Chicago, IL 60611-3008, USA; E-Mail: a-tambur@ * Author to whom correspondence should be addressed; E-Mail: j-wehner@; Tel.: +1-312-503-8069; Fax: +1-312-503-3366. Received: 23 March 2012; in revised form: 30 April 2012 / Accepted: 7 May 2012 / Published: 10 May 2012 Abstract: Immunologic risk in kidney transplantation is typically minimized by avoiding, or at least limiting, the potential of donor specific humoral responses by testing for the presence of donor-specific antibodies (DSA). Additionally, selecting donor and recipient pairs with the least number of human leukocyte antigen (HLA) mismatches has been shown to play a role in transplant outcome. However, numerous other factors may play a role in the success of transplant outcome and patient health. Specifically, the use of T-cell allospecific ELISPOT assays have helped elucidate the role of pre-formed cellular responses as additional factors in post-transplant outcome. In this review, we will evaluate numerous uses of ELISPOT assays to assess the pre- and post-transplant